Royal Bank of Canada’s Checkpoint Therapeutics CKPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-60,158
| Closed | -$243K | – | 7057 |
|
|
2025
Q1 | $243K | Sell |
60,158
-29,757
| -33% | -$99.2K | ﹤0.01% | 4559 |
|
|
2024
Q4 | $288K | Buy |
89,915
+28,992
| +48% | +$98.3K | ﹤0.01% | 4513 |
|
|
2024
Q3 | $136K | Buy |
60,923
+520
| +0.9% | +$1.2K | ﹤0.01% | 5124 |
|
|
2024
Q2 | $130K | Sell |
60,403
-73
| -0.1% | -$130 | ﹤0.01% | 5091 |
|
|
2024
Q1 | $125K | Sell |
60,476
-189
| -0.3% | -$377 | ﹤0.01% | 5055 |
|
|
2023
Q4 | $139K | Sell |
60,665
-550
| -0.9% | -$1.2K | ﹤0.01% | 5394 |
|
|
2023
Q3 | $104K | Sell |
61,215
-1,245
| -2% | -$2.83K | ﹤0.01% | 5357 |
|
|
2023
Q2 | $154K | Buy |
62,460
+910
| +1% | +$2.49K | ﹤0.01% | 4968 |
|
|
2023
Q1 | $139K | Buy |
61,550
+13,387
| +28% | +$67.2K | ﹤0.01% | 4900 |
|
|
2022
Q4 | $246K | Buy |
48,163
+35,511
| +281% | +$256K | ﹤0.01% | 4695 |
|
|
2022
Q3 | $131K | Sell |
12,652
-983
| -7% | -$11.7K | ﹤0.01% | 5124 |
|
|
2022
Q2 | $140K | Sell |
13,635
-9,310
| -41% | -$122K | ﹤0.01% | 5081 |
|
|
2022
Q1 | $406K | Buy |
22,945
+15,927
| +227% | +$342K | ﹤0.01% | 4433 |
|
|
2021
Q4 | $218K | Sell |
7,018
-4
| -0.1% | -$132 | ﹤0.01% | 5247 |
|
|
2021
Q3 | $232K | Buy |
7,022
+690
| +11% | +$20.4K | ﹤0.01% | 5041 |
|
|
2021
Q2 | $187K | Sell |
6,332
-57
| -0.9% | -$1.58K | ﹤0.01% | 5128 |
|
|
2021
Q1 | $200K | Buy |
6,389
+558
| +10% | +$18.7K | ﹤0.01% | 4954 |
|
|
2020
Q4 | $155K | Buy |
5,831
+439
| +8% | +$11.1K | ﹤0.01% | 5044 |
|
|
2020
Q3 | $144K | Buy |
5,392
+6
| +0.1% | +$144 | ﹤0.01% | 4750 |
|
|
2020
Q2 | $107K | Sell |
5,386
-888
| -14% | -$16.2K | ﹤0.01% | 4813 |
|
|
2020
Q1 | $94K | Buy |
6,274
+891
| +17% | +$15.8K | ﹤0.01% | 4813 |
|
|
2019
Q4 | $93K | Sell |
5,383
-215
| -4% | -$3.6K | ﹤0.01% | 5119 |
|
|
2019
Q3 | $139K | Buy |
5,598
+110
| +2% | +$3.02K | ﹤0.01% | 4644 |
|
|
2019
Q2 | $166K | Sell |
5,488
-1,171
| -18% | -$46K | ﹤0.01% | 4584 |
|
|
2019
Q1 | $190K | Hold |
6,659
| – | – | ﹤0.01% | 4388 |
|
|
2018
Q4 | $121K | Sell |
6,659
-5
| -0.1% | -$119 | ﹤0.01% | 4618 |
|
|
2018
Q3 | $238K | Buy |
6,664
+5
| +0.1% | +$175 | ﹤0.01% | 4382 |
|
|
2018
Q2 | $198K | Hold |
6,659
| – | – | ﹤0.01% | 4411 |
|
|
2018
Q1 | $292K | Hold |
6,659
| – | – | ﹤0.01% | 4075 |
|
|
2017
Q4 | $258K | Buy |
+6,659
| New | +$349K | ﹤0.01% | 4263 |
|
Royal Bank of Canada's CKPT Position: Q2 2025 in Review
Royal Bank of Canada sold out of Checkpoint Therapeutics (CKPT) in Q2 2025, closing a stake of 60,158 shares — an estimated $243K sold.
Royal Bank of Canada first reported a position in CKPT in Q4 2017 and held it in 30 quarters. The position peaked at $406K in Q1 2022. 0 funds tracked by Wall St. Rank hold CKPT as of Q2 2025.
- Royal Bank of Canada reported no remaining Checkpoint Therapeutics position as of Q2 2025 after selling out during the quarter.
- Royal Bank of Canada sold 60,158 Checkpoint Therapeutics shares in Q2 2025, an estimated $243K.
- Royal Bank of Canada first reported a position in Checkpoint Therapeutics in Q4 2017 and held it in 30 quarters.
- Royal Bank of Canada's Checkpoint Therapeutics position peaked at $406K in Q1 2022.
- 0 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2025.
Based on Royal Bank of Canada's 13F filing for Q2 2025, filed 14 Aug 2025.